Resource impact statement
No significant resource impact is anticipated
We do not expect this guidance to have a significant impact on resources; that is, it will be less than £1 million per year in England (or £1,800 per 100,000 population).
The guidance is an update to adjunctive colposcopy technologies for examination of the uterine cervix – DySIS and the Niris Imaging System (DG4). The relevant recommendations for routine practice have changed from:
DG4 (published 2012)
- DYSIS is a clinically and cost-effective option, compared with standard colposcopy, for examining the uterine cervix in women referred for colposcopy, and should be considered for procurement plans for colposcopy equipment.
- The Dynamic Spectral Imaging System [DYSIS] colposcope with DYSISmap shows promise and is recommended for assessing suspected cervical abnormalities in people having colposcopy. Centres using the technology should audit their outcomes.
We do not think practice will change substantially as a result of the updated guidance as DYSIS remains a recommended system, and its use is established.
This technology is commissioned by clinical commissioning groups. Providers are NHS hospital trusts.
This page was last updated: 25 April 2018